8th Apr 2022 10:54
Oncimmune Holdings PLC - Nottingham-based immunodiagnostics developer - Signs two further ImmunoInsights commercial contracts. One contract is with an unnamed US-based clinical-stage biopharmaceutical company, that develops cellular immunotherapies for cancer patients. Oncimmune will provide the customer with its biomarker discover platform SeroTag to identify autoantibodies. Second contract is with another US clinical-stage biopharmaceutical company which is developing immune system-related technologies. Read More